Metastatic CRPC Is Common
Most men with castrate-resistant prostate cancer (CRPC) will eventually develop metastatic disease.1-3
Learn more about diagnosing mCRPC
PROVENGE Treatment Window
In the newly metastatic CRPC patient who is asymptomatic or minimally symptomatic, there’s a PROVENGE window.
Learn more about the PROVENGE treatment window
For the Newly Metastatic CRPC Patient
61% of men are PROVENGE-eligible at diagnosis of metastatic CRPC.4
Identify PROVENGE patients
Discuss PROVENGE With Your Patients
Help your patients understand treatment with PROVENGE.
Talk with your patients
A brief overview about PROVENGE, its mechanism of action, clinical data, patient selection, and administration
- Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Current Oncology. 2010;17(S2):S72-S79.
- National Comprehensive Cancer Network. Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. Version 1.2013. 1/20/13.
- Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192.
- Data on file. Dendreon Corporation.